OPTN - OptiNose reports mixed Q3 earnings; narrows FY22 guidance range

• OptiNose press release ( NASDAQ: OPTN ): Q3 GAAP EPS of -$0.18 in-line.
• Revenue of $20.1M (-7.9% Y/Y) misses by $3.3M .
• XHANCE Net Revenue and Average Net Revenue per Prescription: The company expects XHANCE net revenues for the full year of 2022 to be between $74 to $78 million. Previously, the company expected XHANCE net revenues for the full year of 2022 to be between $85 to $92 million. In addition, the Company expects full year 2022 XHANCE average net revenue per prescription to be approximately $220. Previously, the Company expected full year 2022 XHANCE average net revenue per prescription to be at least $220.
• Operating Expenses: The Company expects total GAAP operating expenses (selling, general & administrative expenses and research & development expenses) for 2022 to be in the range of $127 - $131 million, of which the Company expects stock-based compensation to be approximately $9 million. Previously the Company expected total GAAP operating expenses (selling, general & administrative expenses and research & development expenses) for 2022 to be in the range of $129 - $134 million, of which the Company expected stock-based compensation to be approximately $9 million.

• In addition, the company expects total GAAP operating expenses for full year 2023 to decrease materially compared to full year 2022 total GAAP operating expenses.

For further details see: